Zacks Investment Research Lowers OrthoPediatrics (NASDAQ:KIDS) to Sell

Zacks Investment Research cut shares of OrthoPediatrics (NASDAQ:KIDSGet Rating) from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “

Several other research analysts also recently weighed in on the company. Needham & Company LLC lowered their target price on OrthoPediatrics from $83.00 to $65.00 and set a buy rating on the stock in a research note on Thursday, March 3rd. TheStreet cut OrthoPediatrics from a c rating to a d+ rating in a report on Thursday, May 5th. Piper Sandler reduced their price objective on OrthoPediatrics from $80.00 to $55.00 in a report on Thursday, May 5th. Finally, Truist Financial dropped their price target on OrthoPediatrics from $70.00 to $54.00 in a research report on Friday, May 6th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, OrthoPediatrics presently has a consensus rating of Buy and an average price target of $66.00.

Shares of OrthoPediatrics stock opened at $42.11 on Wednesday. The business’s fifty day simple moving average is $49.46 and its 200-day simple moving average is $53.95. OrthoPediatrics has a 52 week low of $36.71 and a 52 week high of $73.91. The firm has a market cap of $851.89 million, a PE ratio of -54.69 and a beta of 0.88.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last posted its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.05. OrthoPediatrics had a negative return on equity of 6.98% and a negative net margin of 14.98%. The company had revenue of $24.81 million for the quarter, compared to analyst estimates of $24.78 million. During the same quarter last year, the company earned ($0.31) EPS. On average, research analysts expect that OrthoPediatrics will post -0.79 earnings per share for the current year.

In related news, Director Mark C. Throdahl sold 5,961 shares of the company’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $58.60, for a total transaction of $349,314.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregory A. Odle sold 4,108 shares of the stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $57.55, for a total transaction of $236,415.40. The disclosure for this sale can be found here. Insiders have sold 22,984 shares of company stock worth $1,334,452 in the last 90 days. 30.30% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of KIDS. Brown Advisory Inc. raised its holdings in OrthoPediatrics by 12.4% during the 1st quarter. Brown Advisory Inc. now owns 1,201,101 shares of the company’s stock worth $64,881,000 after buying an additional 132,537 shares during the period. Riverbridge Partners LLC boosted its position in shares of OrthoPediatrics by 4.3% in the first quarter. Riverbridge Partners LLC now owns 1,153,146 shares of the company’s stock valued at $62,258,000 after acquiring an additional 47,873 shares during the period. Wasatch Advisors Inc. boosted its position in shares of OrthoPediatrics by 0.9% in the fourth quarter. Wasatch Advisors Inc. now owns 499,437 shares of the company’s stock valued at $29,896,000 after acquiring an additional 4,503 shares during the period. Summit Partners Public Asset Management LLC boosted its position in shares of OrthoPediatrics by 11.5% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 436,123 shares of the company’s stock valued at $26,106,000 after acquiring an additional 44,973 shares during the period. Finally, New York State Common Retirement Fund raised its stake in OrthoPediatrics by 13.5% in the first quarter. New York State Common Retirement Fund now owns 435,803 shares of the company’s stock valued at $23,529,000 after purchasing an additional 51,924 shares in the last quarter. 71.51% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

See Also

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.